ReviewClinical and translational imaging2017
Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.
Review in Clinical and translational imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review.International journal of nanomedicine · 2022Pooled it
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Review
- Review
- FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century.Frontiers in oncology · 2022Review
- Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.Neuro-oncology · 2021Article
- The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2021Review
- Maximizing the use of batch production ofNeuro-oncology practice · 2021Article
- Can High b Value Diffusion Be a Surrogate Marker for PET-A MR/PET Study in Neurooncology Set Up.Frontiers in neurology · 2021Article
- Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.AJNR. American journal of neuroradiology · 2020Review
- Advances in simultaneous PET/MR for imaging neuroreceptor function.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020Review
- Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination.PloS one · 2020Article
- The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence.Diagnostics (Basel, Switzerland) · 2019Review
- Impact of non-uniform attenuation correction in a dynamic [EJNMMI research · 2019Article
- Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods.European radiology · 2019Article
- Hybrid PET/MRI imaging in healthy unsedated newborn infants with quantitative rCBF measurements usingJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
- MRI-Driven PET Image Optimization for Neurological Applications.Frontiers in neuroscience · 2019Review
- Comparisons of the accuracy of radiation diagnostic modalities in brain tumor: A nonrandomized, nonexperimental, cross-sectional trial.Medicine · 2018Article
- The vast potential and bright future of neuroimaging.The British journal of radiology · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMagnetic resonance imaging (MRI) plays a key role in neurooncology, i.e., for diagnosis, treatment evaluation and detection of recurrence. However, standard MRI cannot always separate malignant tissue from other pathologies or treatment-induced changes. Advanced MRI techniques such as diffusion-weighted imaging, perfusion imaging and spectroscopy show promising results in discriminating malignant from benign lesions. Further, supplemental imaging with amino acid positron emission tomography (PET) has been shown to increase accuracy significantly and is used routinely at an increasing number of sites. Several centers are now implementing hybrid PET/MRI systems allowing for multiparametric imaging, combining conventional MRI with advanced MRI and amino acid PET imaging. Neurooncology is an obvious focus area for PET/MR imaging.
methodsBased on the literature and our experience from more than 300 PET/MRI examinations of brain tumors with
resultsAlthough the results are increasingly promising, the added value and range of indications for multiparametric imaging with PET/MRI are yet to be established. Robust solutions to overcome the number of issues when using a PET/MRI scanner are being developed, which is promising for a more routine use in the future.
conclusionsIn a clinical setting, a PET/MRI scan may increase accuracy in discriminating recurrence from treatment changes, although sequential same-day imaging on separate systems will often constitute a reliable and cost-effective alternative. Pediatric patients who require general anesthesia will benefit the most from simultaneous PET and MR imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.